(1) How many (a) prisoners and (b) awaiting-trial detainees in prisons (i) have been diagnosed with and (ii) are receiving treatment for (aa) Type 1 diabetes and (bb) Type 2 diabetes; (2) do (a) awareness campaigns on or (b) regular testing for diabetes take place in prisons; if so, in each case, (i) which department or entity is responsible and (ii) how often do these take place; (3) what (a) equipment and (b) medication are made available to inmates for the (i) treatment and (ii) monitoring of (aa) diabetes and (bb) related conditions; (4) what is the average cost for each inmate for the treatment and monitoring of (a) diabetes and (b) related conditions?